

Tanya B Dorff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/473904/publications.pdf>

Version: 2024-02-01

95
papers

3,599
citations

257450

24
h-index

144013

57
g-index

97
all docs

97
docs citations

97
times ranked

5457
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1036-1039.	6.3	74
2	Prostate Cancer Characteristics and Outcomes after Prostatectomy in Asian-American Men. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 92-92.e6.	1.9	2
3	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 388-396.	3.9	15
4	Novel Redirected T ^H 1 Cell Immunotherapies for Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 576-584.	7.0	26
5	Changes in perception of immunotherapy over time among patients with advanced genitourinary cancers. <i>Journal of Clinical Oncology</i> , 2022, 40, 328-328.	1.6	0
6	Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. <i>Nature Medicine</i> , 2022, 28, 704-712.	30.7	181
7	PD-L1 blockade restores CAR T cell activity through IFN- γ -regulation of CD163+ M2 macrophages. , 2022, 10, e004400.		16
8	Editorial summary: A paradigm shift in castration-resistant prostate cancer management. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 601-603.	3.9	3
9	Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 61-68.	3.9	34
10	The Role of Diverse Populations in US Clinical Trials. <i>Med</i> , 2021, 2, 21-24.	4.4	14
11	High-throughput global transcriptional profiling to identify the STAT3 signaling pathway as a potential biomarker for immune checkpoint inhibitor resistance in metastatic/advanced urothelial carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 474-474.	1.6	0
12	The effects of bright white light therapy on obese frailty in older men with prostate cancer on hormonal therapy: A pilot randomized control trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 75-75.	1.6	0
13	Wnt/ β -Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma. <i>Cancers</i> , 2021, 13, 889.	3.7	24
14	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 134-143.	4.9	299
15	Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 125-134.	1.9	4
16	Role of Ki-67, MRE11, and PD-L1 as Predictive Biomarkers for Recurrence Pattern in Muscle-invasive Bladder Cancer. <i>Anticancer Research</i> , 2021, 41, 3851-3857.	1.1	1
17	Hormonal manipulation in androgen signaling: a narrative review on using novel androgen therapy agents to optimize clinical outcomes and minimize side effects for prostate cancer patients. <i>Translational Andrology and Urology</i> , 2021, 10, 3199-3207.	1.4	6
18	Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. <i>Molecular Therapy</i> , 2021, 29, 2335-2349.	8.2	51

#	ARTICLE	IF	CITATIONS
19	Salvage therapy for prostate cancer after radical prostatectomy. <i>Nature Reviews Urology</i> , 2021, 18, 643-668.	3.8	26
20	Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T. , 2021, 9, e002931.		18
21	Characterizing Out-of-Pocket Payments and Financial Assistance for Patients Prescribed Abiraterone and Enzalutamide at an Academic Cancer Center Specialty Pharmacy. <i>JCO Oncology Practice</i> , 2021, , OP.21.00574.	2.9	1
22	25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 521-527.	1.6	3
23	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 83-93.	1.6	24
24	NCIâ€“Clinical Trial Accrual in a Community Network Affiliated with a Designated Cancer Center. <i>Journal of Clinical Medicine</i> , 2020, 9, 1970.	2.4	4
25	Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 485-489.	1.0	2
26	Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. <i>European Urology</i> , 2020, 77, 614-627.	1.9	101
27	Chemoradiation for Management of Locally Recurrent or Residual Bladder Cancer: A Case Series and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e473-e477.	1.9	1
28	Cancer transcriptomic profiling from rapidly enriched circulating tumor cells. <i>International Journal of Cancer</i> , 2020, 146, 2845-2854.	5.1	7
29	<i>CDK12</i>-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. <i>JCO Precision Oncology</i> , 2020, 4, 382-392.	3.0	51
30	COVID-19 and androgen-targeted therapy for prostate cancer patients. <i>Endocrine-Related Cancer</i> , 2020, 27, R281-R292.	3.1	64
31	Defining Value in Metastatic Prostate Cancer: What Is the Cost of Living Longer and Better?. <i>JCO Oncology Practice</i> , 2020, 16, 53-54.	2.9	1
32	The Evolving Role of Prostate-Specific Membrane Antigenâ€“Based Diagnostics and Therapeutics in Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 321-330.	3.8	33
33	Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). <i>Clinical Genitourinary Cancer</i> , 2019, 17, 241-247.e1.	1.9	11
34	Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy. , 2019, 7, 71.		21
35	Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 50-60.	0.8	21
36	Impact of timing of administration of bone supportive therapy on pain palliation from radium-223. <i>Cancer Treatment and Research Communications</i> , 2019, 18, 100114.	1.7	9

#	ARTICLE	IF	CITATIONS
37	Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 1-11.	1.6	11
38	Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). <i>Clinical Genitourinary Cancer</i> , 2018, 16, e11-e21.	1.9	9
39	Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 90-98.e1.	1.9	11
40	Bone-targeted therapies to reduce skeletal morbidity in prostate cancer. <i>Asian Journal of Andrology</i> , 2018, 20, 215.	1.6	14
41	Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target. <i>Journal of Clinical Medicine</i> , 2018, 7, 156.	2.4	10
42	Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. <i>Hepatology</i> , 2018, 68, 1412-1428.	7.3	48
43	Low-dimensional dynamical characterization of human performance of cancer patients using motion data. <i>Clinical Biomechanics</i> , 2018, 56, 61-69.	1.2	5
44	Phase I study of stereotactic body radiotherapy following radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS158-TPS158.	1.6	1
45	Multi-parametric liquid biopsy analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and cell-free RNA (cfRNA) in metastatic castrate resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 274-274.	1.6	3
46	High dose interleukin-2 and response in 944 patients with metastatic renal cell cancer (RCC): Data from the PROCLAIM registry.. <i>Journal of Clinical Oncology</i> , 2018, 36, 624-624.	1.6	1
47	Novel method for rapid enrichment of high purity circulating tumor cells (CTCs) for prostate cancer (PCa) gene expression profiling.. <i>Journal of Clinical Oncology</i> , 2018, 36, 271-271.	1.6	0
48	Immune-related adverse events (irAE) in GU cancer patients receiving immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 422-422.	1.6	0
49	Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	363
50	Robotic salvage retroperitoneal and pelvic lymph node dissection for "node-only" recurrent prostate cancer: technique and initial series. <i>BJU International</i> , 2017, 120, 401-408.	2.5	27
51	Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. <i>Cancer</i> , 2017, 123, 4566-4573.	4.1	37
52	A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 742-749.	1.9	21
53	Chemotherapy for oligometastatic prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 553-558.	1.8	4
54	A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy. <i>BMJ Open</i> , 2017, 7, e016910.	1.9	14

#	ARTICLE	IF	CITATIONS
55	Current Management Strategy for Penile Cancer and Future Directions. <i>Current Oncology Reports</i> , 2017, 19, 54.	4.0	10
56	Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: A phase III intergroup trial (SWOG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	0
57	Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: A phase III intergroup trial (SWOG) Tj ETQq1 1 0.784314 rgBT /Overlock	1.6	0
58	Impact of resistance exercise on metabolic syndrome (MetS) parameters in men receiving androgen deprivation therapy (ADT) for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 223-223.	1.6	1
59	A phase II trial of zoletarelin doxorubicin in castration- and taxane-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 210-210.	1.6	1
60	Comprehensive genomic profiling of urethral cancer to reveal distinctive features compared to bladder cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 429-429.	1.6	0
61	Randomized phase II trial of abiraterone +/- dasatinib for patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 167-167.	1.6	1
62	Adjuvant androgen deprivation (AD) +/- mitoxantrone + prednisone (MP) in patients with high-risk prostate cancer (PC) post radical prostatectomy (RP): Phase III intergroup trial S9921.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5019-5019.	1.6	0
63	Impact of timing of administration of bone supportive therapy on pain palliation from radium-223.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5023-5023.	1.6	1
64	Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 466-477.	0.3	3
65	Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 543-551.	0.3	6
66	Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 450-456.e1.	1.9	6
67	Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 2478-2483.	1.6	31
68	Adjuvant chemotherapy for bladder cancer: A detailed characterization of factors precluding utilization.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16001-e16001.	1.6	0
69	Outcomes in neuroendocrine bladder cancer treated with radical cystectomy.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16004-e16004.	1.6	0
70	Immunomodulation by HDAC inhibition: Results from a phase II study with entinostat and high-dose interleukin 2 in metastatic renal cell carcinoma patients (CTEP#7870).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4560-4560.	1.6	0
71	Relapsed and refractory germ cell tumors: Finessing the rough end of a beautiful story. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 341-342.	1.6	1
72	A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan. <i>Cell Metabolism</i> , 2015, 22, 86-99.	16.2	635

#	ARTICLE	IF	CITATIONS
73	Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors. <i>Urologic Clinics of North America</i> , 2015, 42, 347-357.	1.8	4
74	Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 6277-6283.	7.0	39
75	Novel tyrosine kinase inhibitors for renal cell carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 67-73.	3.1	9
76	Durable Complete Remission From Castration-Resistant Prostate Cancer With Sipuleucel-T After Estrogen Withdrawal. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e55-e58.	1.9	1
77	Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: A critical analysis of 1,994 patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 52.e1-52.e9.	1.6	55
78	Epidermal Growth Factor Receptor-targeted Therapy in Squamous Cell Carcinoma of the Penis: A Report of 3 Cases. <i>Urology</i> , 2014, 83, 159-166.	1.0	30
79	Clinicopathologic Characteristics and Outcomes of Penile Cancer Treated at Tertiary Care Centers in the Western United States. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 138-142.	1.9	15
80	Prolonged Fasting Reduces IGF-1/PKA to Promote Hematopoietic-Stem-Cell-Based Regeneration and Reverse Immunosuppression. <i>Cell Stem Cell</i> , 2014, 14, 810-823.	11.1	369
81	Baseline ¹⁸ F-FDG PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate-Resistant Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1195-1201.	5.0	110
82	Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer. <i>Current Opinion in Urology</i> , 2013, 23, 366-371.	1.8	16
83	Changes in circulating tumor cells (CTC) and markers of inflammation after sipuleucel-T treatment. <i>Journal of Clinical Oncology</i> , 2013, 31, 40-40.	1.6	1
84	Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. <i>BJU International</i> , 2012, 109, 846-854.	2.5	101
85	A phase I trial of AEZS-108 (AN-152) in castration- and taxane-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 60-60.	1.6	0
86	Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 2040-2045.	1.6	94
87	Use of Testosterone Replacement Therapy in Patients with Prostate Cancer. <i>Current Urology Reports</i> , 2011, 12, 223-228.	2.2	8
88	The Epothilones: New Therapeutic Agents for Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2011, 16, 1349-1358.	3.7	18
89	Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. <i>BJU International</i> , 2010, 105, 1397-1401.	2.5	58
90	Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNT0328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 3028-3034.	7.0	187

#	ARTICLE	IF	CITATIONS
91	Cabazitaxel in prostate cancer: stretching a string. <i>Lancet, The</i> , 2010, 376, 1119-1120.	13.7	13
92	Review: Targeted therapy in renal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2009, 1, 183-205.	3.2	16
93	Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. <i>World Journal of Urology</i> , 2009, 27, 39-44.	2.2	11
94	Evolving treatment paradigms for locally advanced and metastatic prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1639-1651.	2.4	3
95	Ethnic differences in neuroendocrine cell expression in normal human prostatic tissue. <i>Urology</i> , 2005, 65, 1008-1012.	1.0	11